REQUA, INC. – Trademark Portfolio

Entity Type: 03

REQUA, INC. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include REQUA. The owner is based in East Longmeadow, MA.

302 Benton Drive

East Longmeadow, MA 01028

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

REQUA, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

8
Hand Tools (1 filing)

Hand tools and implements (hand-operated); cutlery; side arms; razors

Frequently Asked Questions

How many trademarks does REQUA, INC. have?

REQUA, INC. has 8 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 6 cancelled.

What trademark classes does REQUA, INC. file in?

REQUA, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 8 (Hand Tools). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are REQUA, INC.'s most well-known trademarks?

REQUA, INC.'s registered trademark portfolio includes well-known marks such as REQUA. These are among 1 currently registered trademark in the portfolio.

What is REQUA, INC.'s trademark registration success rate?

REQUA, INC. has a 13% trademark registration rate, with 1 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.